Citadel Advisors
ZNTL icon

Citadel Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Citadel Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.4K Buy
+13,000
New +$33.6K ﹤0.01% 12567
2025
Q2 		– Sell
-7,900
Closed -$12.6K – 15453
2025
Q1 		$12.6K Buy
7,900
+500
+7% +$1.08K ﹤0.01% 13438
2024
Q4 		$22.4K Sell
7,400
-12,300
-62% -$40.3K ﹤0.01% 13105
2024
Q3 		$72.5K Sell
19,700
-13,600
-41% -$49.4K ﹤0.01% 11508
2024
Q2 		$136K Buy
33,300
+7,900
+31% +$88.2K ﹤0.01% 10480
2024
Q1 		$400K Sell
25,400
-31,300
-55% -$431K ﹤0.01% 8862
2023
Q4 		$859K Buy
56,700
+44,400
+361% +$648K ﹤0.01% 6972
2023
Q3 		$247K Sell
12,300
-1,900
-13% -$48.2K ﹤0.01% 9523
2023
Q2 		$401K Sell
14,200
-100
-0.7% -$2.4K ﹤0.01% 8411
2023
Q1 		$246K Sell
14,300
-10,600
-43% -$215K ﹤0.01% 9796
2022
Q4 		$501K Sell
24,900
-26,300
-51% -$566K ﹤0.01% 8226
2022
Q3 		$1.11M Buy
51,200
+31,100
+155% +$850K ﹤0.01% 6778
2022
Q2 		$565K Sell
20,100
-2,800
-12% -$74.2K ﹤0.01% 8375
2022
Q1 		$1.06M Buy
22,900
+2,500
+12% +$135K ﹤0.01% 7562
2021
Q4 		$1.72M Buy
20,400
+7,600
+59% +$588K ﹤0.01% 6608
2021
Q3 		$853K Buy
12,800
+3,900
+44% +$225K ﹤0.01% 8544
2021
Q2 		$473K Buy
+8,900
New +$477K ﹤0.01% 10174

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's ZNTL Position: Q1 2026 in Review

Citadel Advisors reduced its Zentalis Pharmaceuticals (ZNTL) stake by 12% in Q1 2026, selling an estimated $600K and leaving 1,732,083 shares worth $4.05M. The position accounts for ﹤0.01% of the portfolio, ranked #4691.

Citadel Advisors first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $78.1M in Q4 2020. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Citadel Advisors held 1,732,083 shares of Zentalis Pharmaceuticals worth $4.05M as of Q1 2026.
  • Citadel Advisors sold 232,172 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $600K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4691 holding.
  • Citadel Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Zentalis Pharmaceuticals position peaked at $78.1M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.